{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:18:49Z","timestamp":1775791129879,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00108-020-00813-0","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T12:02:52Z","timestamp":1590580972000},"page":"652-659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CD28-Kostimulation und Checkpointblockade in T-Zellen","CD28 costimulation and checkpoint inhibition in T cells"],"prefix":"10.1007","volume":"61","author":[{"given":"N.","family":"Beyersdorf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kerkau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"813_CR1","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber\u00a0DL, Wherry\u00a0EJ, Masopust\u00a0D et\u00a0al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682\u2013687","journal-title":"Nature"},{"key":"813_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fimmu.2012.00211","volume":"3","author":"F Barzaghi","year":"2012","unstructured":"Barzaghi\u00a0F, Passerini\u00a0L, Bacchetta\u00a0R (2012) Immune dysregulation, polyendocrinopathy, enteropathy, x\u2011linked syndrome: a\u00a0paradigm of immunodeficiency with autoimmunity. Front Immunol 3:211","journal-title":"Front Immunol"},{"key":"813_CR3","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-10-0569","volume":"16","author":"BC Carthon","year":"2010","unstructured":"Carthon\u00a0BC, Wolchok\u00a0JD, Yuan\u00a0J et al (2010) Preoperative CTLA\u20114 blockade: tolerability and immune monitoring in the setting of a\u00a0presurgical clinical trial. Clin Cancer Res 16:2861\u20132871","journal-title":"Clin Cancer Res"},{"key":"813_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen\u00a0L, Flies\u00a0DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13:227\u2013242","journal-title":"Nat Rev Immunol"},{"key":"813_CR5","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran\u00a0MA, Montalvo\u00a0W, Yagita\u00a0H et al (2010) PD\u20111 and CTLA\u20114 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S\u00a0A 107:4275\u20134280","journal-title":"Proc Natl Acad Sci U S A"},{"key":"813_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1084\/jem.20040165","volume":"200","author":"MR Ehrenstein","year":"2004","unstructured":"Ehrenstein\u00a0MR, Evans\u00a0JG, Singh\u00a0A et al (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J\u00a0Exp Med 200:277\u2013285","journal-title":"J Exp Med"},{"key":"813_CR7","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz\u00a0A, Shin\u00a0DS, Moreno\u00a0BH et al (2017) Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 19:1189\u20131201","journal-title":"Cell Rep"},{"key":"813_CR8","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon\u00a0EB, Rizvi\u00a0NA, Hui\u00a0R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N\u00a0Engl J Med 372:2018\u20132028","journal-title":"N Engl J Med"},{"key":"813_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin\u00a0MM, Zhang\u00a0X, Schuster\u00a0H et al (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577\u2013581","journal-title":"Nature"},{"key":"813_CR10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann\u00a0MD, Ciuleanu\u00a0TE, Pluzanski\u00a0A et\u00a0al (2018) Nivolumab plus ipilimumab in lung cancer with a\u00a0high tumor mutational burden. N\u00a0Engl J Med 378:2093\u20132104","journal-title":"N Engl J Med"},{"key":"813_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst\u00a0RS, Soria\u00a0JC, Kowanetz\u00a0M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563\u2013567","journal-title":"Nature"},{"key":"813_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi\u00a0FS, O\u2019Day\u00a0SJ, McDermott\u00a0DF et\u00a0al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N\u00a0Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"813_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang\u00a0AC, Postow\u00a0MA, Orlowski\u00a0RJ et al (2017) T\u2011cell invigoration to tumour burden ratio associated with anti-PD\u20111 response. Nature 545:60\u201365","journal-title":"Nature"},{"key":"813_CR14","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida\u00a0Y, Agata\u00a0Y, Shibahara\u00a0K et al (1992) Induced expression of PD\u20111, a\u00a0novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo\u00a0J 11:3887\u20133895","journal-title":"Embo J"},{"key":"813_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1600-065X.2008.00718.x","volume":"227","author":"O Joffre","year":"2009","unstructured":"Joffre\u00a0O, Nolte\u00a0MA, Sporri\u00a0R et\u00a0al (2009) Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 227:234\u2013247","journal-title":"Immunol Rev"},{"key":"813_CR16","doi-asserted-by":"publisher","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","volume":"113","author":"K Klocke","year":"2016","unstructured":"Klocke\u00a0K, Sakaguchi\u00a0S, Holmdahl\u00a0R et al (2016) Induction of autoimmune disease by deletion of CTLA\u20114 in mice in adulthood. Proc Natl Acad Sci U S\u00a0A 113:E2383\u2013E2392","journal-title":"Proc Natl Acad Sci U S A"},{"key":"813_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.182.2.459","volume":"182","author":"MF Krummel","year":"1995","unstructured":"Krummel\u00a0MF, Allison\u00a0JP (1995) CD28 and CTLA\u20114 have opposing effects on the response of T cells to stimulation. J\u00a0Exp Med 182:459\u2013465","journal-title":"J Exp Med"},{"key":"813_CR18","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach\u00a0DR, Krummel\u00a0MF, Allison\u00a0JP (1996) Enhancement of antitumor immunity by CTLA\u20114 blockade. Science 271:1734\u20131736","journal-title":"Science"},{"key":"813_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","volume":"26","author":"TR Malek","year":"2008","unstructured":"Malek\u00a0TR (2008) The biology of interleukin\u20112. Annu Rev Immunol 26:453\u2013479","journal-title":"Annu Rev Immunol"},{"key":"813_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura\u00a0H, Nose\u00a0M, Hiai\u00a0H et al (1999) Development of lupus-like autoimmune diseases by disruption of the PD\u20111 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141\u2013151","journal-title":"Immunity"},{"key":"813_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura\u00a0H, Okazaki\u00a0T, Tanaka\u00a0Y et al (2001) Autoimmune dilated cardiomyopathy in PD\u20111 receptor-deficient mice. Science 291:319\u2013322","journal-title":"Science"},{"key":"813_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41590-018-0289-6","volume":"20","author":"DL Owen","year":"2019","unstructured":"Owen\u00a0DL, Mahmud\u00a0SA, Sjaastad\u00a0LE et\u00a0al (2019) Thymic regulatory T cells arise via two distinct developmental programs. Nat Immunol 20:195\u2013205","journal-title":"Nat Immunol"},{"key":"813_CR23","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas\u00a0A, Hamid\u00a0O, Daud\u00a0A et\u00a0al (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600\u20131609","journal-title":"JAMA"},{"key":"813_CR24","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert\u00a0C, Thomas\u00a0L, Bondarenko\u00a0I et\u00a0al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N\u00a0Engl J Med 364:2517\u20132526","journal-title":"N Engl J Med"},{"key":"813_CR25","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder\u00a0A, Makarov\u00a0V, Merghoub\u00a0T et al (2014) Genetic basis for clinical response to CTLA\u20114 blockade in melanoma. N\u00a0Engl J Med 371:2189\u20132199","journal-title":"N Engl J Med"},{"key":"813_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda\u00a0H, Howson\u00a0JM, Esposito\u00a0L et al (2003) Association of the T\u2011cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506\u2013511","journal-title":"Nature"},{"key":"813_CR27","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nri3108","volume":"11","author":"LS Walker","year":"2011","unstructured":"Walker\u00a0LS, Sansom\u00a0DM (2011) The emerging role of CTLA4 as a\u00a0cell-extrinsic regulator of T cell responses. Nat Rev Immunol 11:852\u2013863","journal-title":"Nat Rev Immunol"},{"key":"813_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse\u00a0P, Penninger\u00a0JM, Timms\u00a0E et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla\u20114. Science 270:985\u2013988","journal-title":"Science"},{"key":"813_CR29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber\u00a0JS, D\u2019Angelo\u00a0SP, Minor\u00a0D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA\u20114 treatment (CheckMate 037): a\u00a0randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384","journal-title":"Lancet Oncol"},{"key":"813_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing\u00a0K, Onishi\u00a0Y, Prieto-Martin\u00a0P et al (2008) CTLA\u20114 control over Foxp3+ regulatory T cell function. Science 322:271\u2013275","journal-title":"Science"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00813-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-020-00813-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-020-00813-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T23:13:36Z","timestamp":1622070816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-020-00813-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s00108-020-00813-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"27 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Beyersdorf und T.\u00a0Kerkau geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}